A phase I/II trial of palbociclib, pembrolizumab, and endocrine therapy for patients with HR+/HER2- locally advanced or metastatic breast cancer (MBC): Clinical outcomes and stool microbial profiling.
Epidemiologic risk factors associated with breast cancer subtypes. Frequency of L858R and D746-750 EGFR mutations in 411 Caucasian patients with non-small cell lung cancer measured by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results